By R.S. Analytics : Incyte Corp. (NASDAQ: INCY ) is a biopharmaceutical company focusing on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. Incyte currently has one drug on the market, a deep pipeline, and multiple ...
By RightEdge Analytics : Background: Unilife Corporation (NASDAQ: UNIS ) is a designer and manufacturer of injectable drug delivery systems worldwide. Unilife offers a diverse product line to satisfy the deployment of drugs ranging from stable vaccines to complex biologics. The whole delivery ...
insulin degludec ( Tresiba ) and liraglutide ( Victoza ). Novo plans to launch the product in Europe in 1H 2015. Related tickers: (NYSE: NVS ) (NYSE: LLY ) (NYSE: MRK ) (NYSE: SNY ) (NYSE: AZN ) (NYSE: GSK ) Post your comment!
Sept 19 (Reuters) - Ypsomed Holding AG : * Says AstraZeneca will use Ypsomed injection system for subcutaneous ad-
is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. Related tickers: ( NVS +0.1% ) ( MRK +0.7% ) ( SNY +0.7% )( AZN +1.3% )( GSK +0.4% ) Post your comment!
* US FDA approved Movantik (Naloxegol) tablets C-II as first once-daily oral peripherally-acting mu-opioid receptor antagonist (pamora) medication
By Trevor Lowenthal : In early June I wrote a bullish article on AstraZeneca (NYSE: AZN ), with a thesis stating that the company's extensive oncology pipeline as well as its attractive buyout prospects in light
Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .
induced constipation who take opioids for the management of chronic non-cancer pain. Movantik is distributed by AstraZeneca ( AZN -0.9% ). Related tickers: ( PGNX -0.2% ) ( SLXP +3.7% ) ( CBST +0.1% ) Post your comment!
partner for its experimental Alzheimer's drug, AstraZeneca (NYSE: AZN ) has now agreed to team up with Eli Lilly (NYSE ..... Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M, depending on the progress of the